Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Oct 5, 2020 09:00AM Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
Oct 5, 2020 07:25AM Corvus Pharmaceuticals (CRVS) Announces Co-Founding of Angel Pharmaceuticals in China
Oct 5, 2020 07:24AM Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in China
Oct 2, 2020 06:11AM Arcutis Biotherapeutics Inc. (ARQT) Prices 4M Share Common Offering and Concurrent Private Placement
Oct 1, 2020 10:47PM Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock
Oct 1, 2020 04:05PM Xtant Medical Announces Closing of Debt Restructuring
Sep 30, 2020 07:54PM Form 4/A Prelude Therapeutics For: Mar 27 Filed by: ORBIMED ADVISORS LLC
Sep 29, 2020 08:11PM Form 4 Prelude Therapeutics For: Sep 25 Filed by: ORBIMED ADVISORS LLC
Sep 29, 2020 04:52PM Arcutis Bio (ARQT) Announces 4M Share Proposed Public Offering and Concurrent $35M Private Placement of Common Stock
Sep 29, 2020 04:51PM Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock
Sep 29, 2020 04:41PM Form 4 GRAYBUG VISION, INC. For: Sep 25 Filed by: ORBIMED ADVISORS LLC
Sep 25, 2020 02:00AM Lysogene Reports First Half 2020 Financial Results and Provides Operational Update
Sep 24, 2020 07:30PM Form 3 GRAYBUG VISION, INC. For: Sep 24 Filed by: ORBIMED ADVISORS LLC
Sep 24, 2020 07:25PM Form 3 Prelude Therapeutics For: Sep 24 Filed by: ORBIMED ADVISORS LLC
Sep 23, 2020 05:10PM Form 4 89bio, Inc. For: Sep 21 Filed by: OrbiMed Advisors Israel II Ltd
Sep 23, 2020 05:01PM Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 23, 2020 08:00AM Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions
Sep 21, 2020 09:00AM Novellus Closes $57M Series C Financing
Sep 18, 2020 05:13PM Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 17, 2020 09:46PM Form 4 Adicet Bio, Inc. For: Sep 15 Filed by: ORBIMED ADVISORS LLC
Aug 31, 2020 07:30AM NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy
Aug 28, 2020 04:15PM Sinovac Reports Unaudited Second Quarter 2020 Financial Results
Aug 25, 2020 04:01PM ReViral Raises $44 Million in Series C Financing
Aug 24, 2020 07:00AM Prelude Therapeutics Announces Closing of $50M Series C Financing
Aug 19, 2020 05:14PM Form SC 13G/A ESSA Pharma Inc. Filed by: ORBIMED ADVISORS LLC
Aug 18, 2020 04:32PM Form SC 13D Acutus Medical, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 18, 2020 07:00AM Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical Officer
Aug 14, 2020 04:54PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 12, 2020 09:06PM Form 4 Acutus Medical, Inc. For: Aug 10 Filed by: ORBIMED ADVISORS LLC
Aug 12, 2020 07:00AM Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade
Aug 11, 2020 06:24PM Form 4 Inspire Medical Systems, For: Aug 07 Filed by: ORBIMED ADVISORS LLC
Aug 10, 2020 08:30AM Xtant Medical Announces Debt Restructuring
Aug 5, 2020 09:05PM Form 3 Acutus Medical, Inc. For: Aug 05 Filed by: ORBIMED ADVISORS LLC
Aug 5, 2020 04:05PM Natera Reports Second Quarter 2020 Financial Results
Aug 3, 2020 08:00AM PMV Pharma Closes $70 Million in Series D Financing
Jul 30, 2020 06:26PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Jul 28, 2020 06:02AM Form SC 13G Pandion Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jul 16, 2020 08:41PM Form 3 Pandion Therapeutics, For: Jul 16 Filed by: ORBIMED ADVISORS LLC
Jul 16, 2020 05:13PM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 13, 2020 04:21PM Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 10, 2020 11:55AM Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 8, 2020 09:00AM Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation
Jul 7, 2020 06:01AM Form SC 13D Fusion Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Jul 1, 2020 05:31PM Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 30, 2020 09:20AM Sinovac Reports Unaudited First Quarter 2020 Financial Results
Jun 30, 2020 06:32AM Form SC 13D Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 26, 2020 06:03AM Form SC 13D Repare Therapeutics Inc. Filed by: ORBIMED ADVISORS LLC
Jun 25, 2020 08:01PM Form 3 Fusion Pharmaceuticals For: Jun 25 Filed by: ORBIMED ADVISORS LLC
Jun 23, 2020 09:37PM Form 4 Compass Therapeutics, For: Jun 19 Filed by: ORBIMED ADVISORS LLC
Jun 23, 2020 09:34PM Form 3 Compass Therapeutics, For: Jun 17 Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed